2024

Pharmacogenomics

Name: Pharmacogenomics
Code: CMS13781I
3 ECTS
Duration: 15 weeks/78 hours
Scientific Area: Biochemistry, Biological Sciences

Teaching languages: Portuguese
Languages of tutoring support: Portuguese, English
Regime de Frequência: Presencial

Presentation

Study of the processes, methodologies and strategies applicable to obtaining new medicinal products from technologies associated with DNA recombination.

Sustainable Development Goals

Learning Goals

The general objectives of this Course are the acquisition of knowledge in the field of pharmacogenomics for integration in the context of molecular and precision medicine. The students must acquire skills in order to understand and apply the general concepts of pharmacogenomics and variations in individual genetic profiles that influence the effectiveness and safety of the instituted therapies. This course will be a fundamental instrument for the future of personalized medicine.
The practical and theoretical-practical exercises to be developed will familiarize students with the applicable methodologies and will serve to consolidate the theoretical knowledge acquired in this context.

Contents

1. Human genetics and general concepts of Pharmacogenomics
2. Basic aspects of pharmacokinetics and pharmacodynamics in the context of different genetic profiles
3. Pharmacogenomics in the discovery and development of new drugs
4. Genetic polymorphisms as a study model in pharmacogenomics
5. Pharmacogenomics and metabolism enzymes: Polymorphisms in enzymes involved in drug metabolism
6. Pharmacogenomics and development of new therapeutic targets
7. Pharmacogenomics in clinical practice: Pharmacogenomic tests and their application in therapy
8. Applications of pharmacogenomics in preventive and personalized medicine
9. Prospects for the future of pharmacogenomics
10. Legal, ethical and social implications of pharmacogenomics
11. Proposal for a new personalized therapy.

Teaching Methods

1. Theoretical exposition
2. Study and discussion of practical cases of effectiveness and safety of drugs dependent on genetic profiles
3. Elaboration and public presentation of thematic monograph

The evaluation of the theoretical component, by continuous assessment of frequencies or final examination, will have a relative weight of 70%.
The practical component will be evaluated by the report of one of the works carried out and will have a relative weight of 15%.
The evaluation of the monograph and its public presentation will have a relative weight of 15%.
If and when it is possible to do all face-to-face teaching, the relative weight of the monograph and the practical component will be reduced to 10% and 10% will be attributed to attendance to all teaching components.